Contract Research & Services
Clinical Trials

Cancer Research UK, Biotecnol to begin trials of novel immuno-oncology treatment

PBR Staff Writer Published 10 August 2017

Cancer Research UK has collaborated with Biotecnol to start early phase clinical trials for new immuno-oncology treatment, Tb535H.

Tb535H, which is an anti-5T4 pan-cancer T-cell engager, will get support from the Cancer Research UK in its early clinical development.

The first-in-class Fdrug is evolved from Biotecnol’s novel antibody development platform called Trisoma.

New immuno-oncology treatment will act against the 5T4/WAIF1 tumour antigen, which is a protein found on multiple different solid tumours.

Tb535H will enroll the patient’s T-cells and directs them to act against tumours, helping the patient’s own immune system to fight cancer.

Cancer Research UK Manchester Institute’s scientists have discovered WAIF1 antigen, which is a crucial target in many different cancer types, including thoracic cancers such as mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC).

As part of the deal, Biotecnol and Cancer Research UK’s Centre for Drug Development will carry out first-in-man Phase I clinical trial of Tb535H.

Biotecnol-sponsored study will use Cancer Research UK’s drug development expertise in return for shareholdings in Biotecnol.

Biotecno CEO Pedro de Noronha Pissarra said: “We’re very proud to work with Cancer Research UK on the development of advanced clinical trial approaches in this competitive and highly promising field of immuno-oncology.”

Cancer Research UK drug development director Dr Nigel Blackburn said: “Without this collaboration it might have been years before this treatment reached patients so we‘re pleased to work with Biotecnol to elevate their novel drug development platform.”

Trisoma platform has been developed for the assembly, engineering and testing of different Tribody molecules with various distinct properties under different structural formats with optimal stability and desired pharmacological properties.

Tribodies are T-cell engaging tri-specific recombinant antibodies that will enroll cytotoxic T lymphocytes.


Image: Cancer Research UK and Biotecno will begin early phase clinical trials of new immuno-oncology treatment. Photo: courtesy of Cancer Research UK.